RxDoctor Payments Data

Amit Choksi, MD

Gastroenterology · Columbia, TNNPI 1376508374

Payments from drug & device makers

$4,052in general payments, 2019–2025

Across 217 payments — averaging $18.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$381
  • Johnson & Johnson$253
  • Pfizer$240
  • Axonics, Inc.$208
  • UCB, Inc.$142
  • plus $812 from 17 others

What the payments were for

  • Food & beverage$4,052100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,052 in reported general payments places this provider in the 50th percentile of 336 gastroenterology providers in Tennessee.

See all gastroenterology providers in Tennessee

Medicare billing

Part B allowed, 2024
$276,383
Medicare patients
1,213
Services billed
2,438

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab41$287,919
LinzessLinaclotide203$168,059
XifaxanRifaximin25$87,035
Pantoprazole Sodium1,074$17,980
Mesalamine22$7,701
Erythromycin Ethylsuccinate11$6,735
Famotidine346$5,570
Omeprazole224$3,922
Budesonide DrBudesonide35$3,615
Lubiprostone21$3,587
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl220$3,273
Sucralfate99$2,373
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl102$1,565
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg64$1,408
Dicyclomine Hcl36$1,003

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$2,018$168,059203 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$100$87,03525 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 336 gastroenterology providers in Tennessee.

Other gastroenterology in Columbia

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →